Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NGM120 |
| Synonyms | |
| Therapy Description |
NGM120 is a monoclonal antibody that targets glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL), which inhibits binding of its ligand GDF15 and downstream signaling (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NGM120 | NGM-120|NGM 120|GFRAL Antagonistic Monoclonal Antibody NGM120 | NGM120 is a monoclonal antibody that targets glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL), which inhibits binding of its ligand GDF15 and downstream signaling (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07033026 | Phase II | NGM120 | An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. | Recruiting | USA | 0 |
| NCT04068896 | Phase I | NGM120 | Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy | Completed | USA | 0 |